These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12757727)

  • 61. Conformational analysis of a farnesyltransferase peptide inhibitor, CVIM.
    Carlacci L
    J Comput Aided Mol Des; 2000 May; 14(4):369-82. PubMed ID: 10815773
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.
    Prendergast GC
    Curr Opin Cell Biol; 2000 Apr; 12(2):166-73. PubMed ID: 10712917
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
    Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
    Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads.
    Perola E; Xu K; Kollmeyer TM; Kaufmann SH; Prendergast FG; Pang YP
    J Med Chem; 2000 Feb; 43(3):401-8. PubMed ID: 10669567
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Non-thiol farnesyltransferase inhibitors: N-(4-acylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
    Kettler K; Sakowski J; Silber K; Sattler I; Klebe G; Schlitzer M
    Bioorg Med Chem; 2003 Apr; 11(7):1521-30. PubMed ID: 12705292
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.
    Curtin ML; Florjancic AS; Cohen J; Gu WZ; Frost DJ; Muchmore SW; Sham HL
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1367-71. PubMed ID: 12657284
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells.
    Frassanito MA; Cusmai A; Piccoli C; Dammacco F
    Br J Haematol; 2002 Jul; 118(1):157-65. PubMed ID: 12100143
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.
    Dinsmore CJ; Bogusky MJ; Culberson JC; Bergman JM; Homnick CF; Zartman CB; Mosser SD; Schaber MD; Robinson RG; Koblan KS; Huber HE; Graham SL; Hartman GD; Huff JR; Williams TM
    J Am Chem Soc; 2001 Mar; 123(9):2107-8. PubMed ID: 11456854
    [No Abstract]   [Full Text] [Related]  

  • 72. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
    J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A new class of highly potent farnesyl diphosphate-competitive inhibitors of farnesyltransferase.
    Aoyama T; Satoh T; Yonemoto M; Shibata J; Nonoshita K; Arai S; Kawakami K; Iwasawa Y; Sano H; Tanaka K; Monden Y; Kodera T; Arakawa H; Suzuki-Takahashi I; Kamei T; Tomimoto K
    J Med Chem; 1998 Jan; 41(2):143-7. PubMed ID: 9457237
    [No Abstract]   [Full Text] [Related]  

  • 74. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.
    Du W; Liu A; Prendergast GC
    Cancer Res; 1999 Sep; 59(17):4208-12. PubMed ID: 10485456
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Aromatic carboxylic acids as farnesyl surrogates in farnesylpyrophosphate-based farnesyltransferase inhibitors.
    Schlitzer M; Sattler I
    Bioorg Med Chem; 1999 Nov; 7(11):2391-5. PubMed ID: 10632048
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo.
    Wiesner J; Kettler K; Sakowski J; Ortmann R; Katzin AM; Kimura EA; Silber K; Klebe G; Jomaa H; Schlitzer M
    Angew Chem Int Ed Engl; 2004 Jan; 43(2):251-4. PubMed ID: 14695623
    [No Abstract]   [Full Text] [Related]  

  • 77. Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.
    Hasvold LA; Wang W; Gwaltney SL; Rockway TW; Nelson LT; Mantei RA; Fakhoury SA; Sullivan GM; Li Q; Lin NH; Wang L; Zhang H; Cohen J; Gu WZ; Marsh K; Bauch J; Rosenberg S; Sham HL
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4001-5. PubMed ID: 14592494
    [TBL] [Abstract][Full Text] [Related]  

  • 78. 4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.
    Angibaud P; Saha AK; Bourdrez X; End DW; Freyne E; Lezouret P; Mannens G; Mevellec L; Meyer C; Pilatte I; Poncelet V; Roux B; Smets G; Van Dun J; Venet M; Wouters W
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4361-4. PubMed ID: 14643326
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RPR 130401, a nonpeptidomimetic farnesyltransferase inhibitor with in vivo activity.
    Vrignaud P; Bissery MC; Mailliet P; Lavelle F
    Ann N Y Acad Sci; 1999; 886():249-51. PubMed ID: 10667231
    [No Abstract]   [Full Text] [Related]  

  • 80. Exploring structure-activity relationships of tricyclic farnesyltransferase inhibitors using ECLiPS libraries.
    Rokosz LL; Huang CY; Reader JC; Stauffer TM; Southwick EC; Li G; Chelsky D; Baldwin JJ
    Comb Chem High Throughput Screen; 2006 Aug; 9(7):545-58. PubMed ID: 16925514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.